



# Vascular changes in diabetic retinopathy—a longitudinal study in the Nile rat

Huishi Toh<sup>1,2</sup> · Alexander Smolentsev<sup>1,2</sup> · Rachel V. Bozadjian<sup>2</sup> · Patrick W. Keeley<sup>2</sup> · Madison D. Lockwood<sup>1,2</sup> · Ryan Sadjadi<sup>1,2</sup> · Dennis O. Clegg<sup>1,2,3</sup> · Barbara A. Blodi<sup>4</sup> · Peter J. Coffey<sup>1,2,5,6</sup> · Benjamin E. Reese<sup>2,7</sup> · James A. Thomson<sup>1,2,3,8,9</sup>

Received: 20 September 2018 / Revised: 11 March 2019 / Accepted: 24 March 2019 / Published online: 17 May 2019  
© United States & Canadian Academy of Pathology 2019

## Abstract

Diabetic retinopathy is the most common microvascular complication of diabetes and is a major cause of blindness, but an understanding of the pathogenesis of the disease has been hampered by a lack of accurate animal models. Here, we explore the dynamics of retinal cellular changes in the Nile rat (*Arvicanthis niloticus*), a carbohydrate-sensitive model for type 2 diabetes. The early retinal changes in diabetic Nile rats included increased acellular capillaries and loss of pericytes that correlated linearly with the duration of diabetes. These vascular changes occurred in the presence of microglial infiltration but in the absence of retinal ganglion cell loss. After a prolonged duration of diabetes, the Nile rat also exhibits a spectrum of retinal lesions commonly seen in the human condition including vascular leakage, capillary non-perfusion, and neovascularization. Our longitudinal study documents a range and progression of retinal lesions in the diabetic Nile rat remarkably similar to those observed in human diabetic retinopathy, and suggests that this model will be valuable in identifying new therapeutic strategies.

## Introduction

Diabetic retinopathy is the leading cause of blindness in adults in the US [1]. Diabetes affects an estimated 422 million people worldwide, and has been increasing

dramatically in recent decades [2]. The percentage of adults living with diabetes has more than doubled since 1980, and the vast majority of them suffer from type 2 diabetes, which is linked to changing patterns of nutrition. Duration of diabetes and glycated hemoglobin (HbA1c) levels are the most consistently reported risk factors for the development of diabetic retinopathy [3–8], which affects about one-third of diabetic patients [9]. Although nutritional management and changes in lifestyle can slow the progression of type 2 diabetes, current therapies are not effective in addressing

**Supplementary information** The online version of this article (<https://doi.org/10.1038/s41374-019-0264-3>) contains supplementary material, which is available to authorized users.

✉ Huishi Toh  
toh@ucsb.edu  
✉ James A. Thomson  
jthomson@morgridgeinstitute.org

<sup>1</sup> Center for Stem Cell Biology and Engineering, University of California at Santa Barbara, Santa Barbara, CA, USA

<sup>2</sup> Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, CA, USA

<sup>3</sup> Department of Molecular, Cellular, and Developmental Biology, University of California at Santa Barbara, Santa Barbara, CA, USA

<sup>4</sup> University of Wisconsin Fundus Photograph Reading Center, University of Wisconsin, Madison, WI, USA

<sup>5</sup> NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK

<sup>6</sup> The London Project to Cure Blindness, ORBIT, Institute of Ophthalmology, University College London (UCL), London, UK

<sup>7</sup> Department of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, CA, USA

<sup>8</sup> Morgridge Institute for Research, Madison, WI, USA

<sup>9</sup> Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

diabetic retinopathy. Thus there is a compelling need for new therapies, and this will require a better understanding of the pathogenesis of the disease.

The literature on diabetic retinopathy in humans and animal models mainly suggests that pericyte loss is the initiating event [10–12]. However, alternative initiating events have been considered for decades. For example, inflammation has been proposed as the initiating event [13], and as early as 1961, Wolter suggested that loss of neurons may be the primary event that subsequently gives rise to vascular changes [14]. Over 50 years later, controversy surrounding the early changes of diabetic retinopathy persists. A major obstacle to addressing this issue is the lack of adequate human material and the inability to reproduce human features of diabetic retinopathy accurately in an animal model.

Vision loss in diabetic patients primarily results from macular edema, proliferative diabetic retinopathy, and retinal ischemia. Diabetic macular edema is caused by a disruption of the blood retinal barrier and can occur at any point in the progression of the disease when sufficient retinal leakage leads to swelling of the retinal tissue [15]. Proliferative diabetic retinopathy occurs at an advanced stage when neovascularization and fibrosis develop on the retinal surface. The abnormal new vessels are prone to hemorrhage which can contribute to vision loss [16]. In many cases, fibrosis of the new vessels can cause tractional retinal detachment. Diabetic retinal ischemia is characterized by localized regions void of vascular and photoreceptors cells, and can be seen both in patients with proliferative diabetic retinopathy and with diabetic macular edema [17].

Although previously described rodent models replicate some aspects of human diabetic retinopathy, none faithfully reflects the range and progression of lesions present in the human disease [18–20]. Type 2 diabetes is a complex disease with a poorly understood etiology, but it is associated with excess dietary carbohydrates [21, 22]. The Nile rat spontaneously develops type 2 diabetes when fed a diet that has a higher carbohydrate content than its natural diet [23–26]. Others have reported retinal vascular abnormalities [27] and delayed photopic ERG oscillatory potentials [28] in older diabetic Nile rats, but these studies failed to examine the very earliest stages of diabetic retinopathy. Here, we report a detailed chronology of early cellular changes in the retina of diabetic Nile rats and find that the range of advanced lesions observed closely mimics the human disease.

## Materials and methods

### Animals

All animal experiments were approved by the University of California, Santa Barbara, Institutional Animal Care and Use

Committee, and conducted in accord with the NIH Guide for the Care and Use of Laboratory Animals. The Nile rats were either on a high fiber rabbit diet (Lab Diet 5326; Newco Speciality, Rancho Cucamonga, CA, USA) to prevent diabetes, or on a standard rodent diet (Diet 5008; Newco Speciality, Rancho Cucamonga, CA, USA) to induce diabetes [29]. Routine monitoring included measurement of weight and random blood glucose (RBG) every 4 weeks, commencing at weaning. Based on previous studies [30], we considered animals with  $RBG < 75$  mg/dL not to be diabetic,  $75 \leq RBG < 100$  mg/dL to be pre-diabetic, and  $RBG \geq 100$  mg/dL to be diabetic. Our founder Nile rats came from the Brandeis University colony of the Hayes K.C. laboratory.

### Retinal tissue preparation

For post-mortem analysis of retinas, Nile rats were perfusion-fixed with 4% paraformaldehyde (PFA) after being deeply anesthetized with sodium pentobarbital (120 mg/kg, i.p.; Euthasol; Virbac, Fort Worth, TX, USA). Blood was drawn from the heart for hemoglobin analysis shortly before each perfusion. Each Nile rat was perfused with 5 mL of 0.9% saline via syringe, followed by 30 mL of 4% PFA in 0.1 M sodium phosphate buffer (pH 7.2) for 10 min. The eyes were enucleated and immersion-fixed in 4% PFA for 10 min, and transferred to phosphate-buffered saline (PBS) containing 0.1% sodium azide for storage.

### HbA1c analysis

The cardiac blood was collected in an EDTA-coated microvette (Sarstedt AG and Co., Numbrecht, Germany) and frozen at  $-20^{\circ}\text{C}$ . We analyzed the thawed blood for glycated hemoglobin A1c content using the mouse hemoglobin A1c kit (Crystal Chem, Downers Grove, IL).

### Measurement for retinal thickness

To measure the retinal thickness, dissected whole retinas were laid flat on a cellulose membrane, embedded in 5% agarose, and sectioned perpendicularly at 200  $\mu\text{m}$  intervals on a PELCO easiSlicer™. Only sections that included the nerve head and extended to each peripheral edge were used for the thickness analysis. Hoechst 33342 (H3750, Life Technologies) was used for nuclear staining. The retinal thickness was sampled at 100, 200, 300, 400, and 500  $\mu\text{m}$  from the optic nerve head and an average central retinal thickness was determined.

### Immunohistochemistry

Retinas were dissected, and wholemounts were prepared by making four relieving cuts, one in each quadrant, to permit

the retina to lay flat. Retinal wholemounts or transverse sections were then stained with isolectin GS-IB<sub>4</sub> conjugated to Alexa-647 (I32450, ThermoFisher Scientific), diluted 1:100 to label blood vessels and microglial cells and immunostained using a combination of antibodies to the following antigens: Brn3b (sc6026 Santa Cruz), diluted 1:250 to label retinal ganglion cells; Desmin (sc7559, Santa Cruz), diluted 1:500, and NG2 (gift from W. Stallcup lab in Sanford Burnham Prebys) [31], diluted 1:1000 to label pericytes; Iba1 (016-26461, Wako), diluted 1:1000 to label microglia; GFAP conjugated to Cy3 (C9205, Sigma), diluted 1:400 to label astrocytes and reactive Müller glia, and Collagen IV (AB769 Millipore), diluted 1:500 to label blood vessels. The secondary antibodies were raised in donkey, conjugated to IgG-Alexa488, IgG-Alexa594, or IgG-Alexa647 (ThermoFisher Scientific), diluted 1:200. All immunostaining steps included incubation with 5% donkey serum for 24 h, primary antibodies for 3 days, and secondary antibodies for 24 h, all at 4 °C with gentle agitation. The antibodies were diluted in 1% Triton-PBS.

### Stereological cell counting

Retinal ganglion cells and microglial cells were counted using an Optical Fractionator (MBF BioScience) throughout the entire thickness of the retina. The Optical Fractionator estimates the total number of cells using cell counts sampled with Systematic Random Sampling (SRS) [32]. The periodicity of the sampling grid was 700 μm × 700 μm, while the sampled field at each location was 30 μm × 30 μm for retinal ganglion cell counts and 90 μm × 90 μm for microglial cell counts.

### Fundus fluorescein angiography

After brief anesthesia with isoflurane, the rats were given an intramuscular injection of Midazolam (3 mg/kg; Akorn Inc., Lake Forest, IL, USA). Standard procedures were followed using the Phoenix MicronIV (Phoenix Research Laboratories, Pleasanton, CA) to perform fundus fluorescein angiography (FFA). Materials included 1% tropicamide ophthalmic solution, 2.5% phenylephrine hydrochloride ophthalmic solution (Paragon BioTeck, Inc., Portland, OR, USA), GONAK Hypromellose Ophthalmic Demulcent Solution, and AK-Fluor 10% fluorescein (intraperitoneal injection, 1 μl/g body weight). All ophthalmic solutions and fluorescein were from Akorn Inc. (Lake Forest, IL, USA), unless otherwise indicated.

### Retinal trypsin digest

The retinas were digested with trypsin as described [33] with the following exceptions. After 24 h in water, the

retinas were transferred to a 1% Triton solution for 1 h, and then were incubated at 37 °C in a solution of 3% trypsin (Gibco 1:250) for 2 h. The following day, Periodic Acid Schiff staining was performed as described [34]. A representative trypsin digest of a whole diabetic Nile rat retina is presented in Supplemental Fig. 1.

### Retinal diameter measurements

Trypsin digested samples were imaged at ×40 magnification. Measurements of retinal vessel diameters were obtained with the Vessel Assessment and Measurement Platform for Images of the RETina (VAMPIRE) software suite [35]. Six largest arteries and veins were used to compute the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

### Quantification of cellular changes

Micrographs for quantification were taken with a Canon Rebel XSi digital camera (Canon, Tokyo, Japan) attached to an Olympus CKX41 microscope via an LM scope C-mount. For acellular capillary counts and pericyte processes, 12 micrographs were taken from 3 randomly selected areas in each of the 4 retinal quadrants and analyzed at a final magnification of ×200 (Fig. 1b). The total area used for quantification corresponded to approximately 8.5% of whole retinal area. For pericytes and endothelial cells, 8 micrographs were captured, 2 from each quadrant at ×400 magnification. The counts were quantified using FIJI computer software by two masked graders.


### Statistical analysis

The relationship between the number of acellular capillaries in the left and right eye was tested using Pearson's correlation. To verify if the Kaplan–Meier curves were significantly different from each other, we used Wilcoxon tests. We performed linear regression to analyze the continuous progression of diabetic retinopathy. All statistical analysis was performed on IBM SPSS Statistic software, version 24 and Prism 7.

## Results

### Retinal acellular capillaries

Acellular capillaries are degenerate vascular segments that can appear as empty basement membrane tubes or more frequently, as coarse string remnants. Although a limited number of acellular capillaries can be found in a healthy retina [36], an increased number of acellular capillaries is a



**Fig. 1** Increased acellular capillaries characterize retinopathy in diabetic Nile rats. **a** Trypsin digest micrograph of a diabetic retina. Arrows = acellular capillaries; arrowheads = pericyte processes. Scale bar = 50  $\mu$ m. **b** Representative retinal trypsin digest, 12 fields sampled per retina, 3 per quadrant. Scale bar = 1 mm. **c** Distribution of diabetic ( $n = 64$ ) versus control Nile rats ( $n = 30$ ) across increasing acellular capillaries. These Nile rats were between 20 and 80 weeks old.


Standard deviation is reported beside the mean. **d** Distribution of the same cohort of Nile rats as panel (c) across increasing pericyte processes. **e** Significantly increased acellular capillaries in old Nile rats ( $n = 17$ ) compared to young Nile rats ( $n = 6$ ) in the diabetic group,  $p < 0.05$ . No significant difference between old Nile rats ( $n = 18$ ) and young Nile rats ( $n = 15$ ) in the control group. Old rats = 64–72 weeks old. Young rats = 24–32 weeks old

discriminant feature of diabetic retinopathy [37]. Acellular capillaries must be distinguished from the thin wispy lines of processes resulting from pericyte migration (Fig. 1a) [38]. We counted acellular capillaries and pericyte processes in trypsin digested retinas (Fig. 1b). Diabetic rats had nearly three times the number of acellular capillaries compared to the controls (Fig. 1c). In comparison, the number of pericyte processes did not differ between the diabetic and control groups (Fig. 1d). Acellular capillaries increased marginally with age in control animals, but increased dramatically in age-matched diabetic animals (Fig. 1e). Because diabetic retinopathy is a bilateral disease, we confirmed that the numbers of acellular capillaries in each eye of 21 pairs of retinas were highly correlated

(Supplementary Fig. 2). For the remainder of the study, we relied only on counts from one eye per Nile rat. In animals without diabetes, the number of acellular capillaries ranged from 5.8 to 16.2 acellular capillaries per  $\text{mm}^2$ . Therefore, we defined diabetic animals with over 16.2 acellular capillaries per  $\text{mm}^2$  as having retinopathy.

### Early changes in the diabetic retina

To capture the early events of diabetic retinopathy, we examined Nile rats on a standard rodent diet as duration of diabetes increased up to 36 weeks. In individual rats, counts were obtained from acellular capillaries, pericytes, endothelial cells, microglial cells, and retinal ganglion cells. We



**Fig. 2** Early retinal cellular changes in diabetic Nile rats. Cell number trends of endothelial cells, pericytes, and acellular capillaries (**a**) and pericyte to endothelial cell ratios (**b**) as diabetes progresses.  $N = 48$  rats from 20 to 44 weeks old. **c** Micrographs showing evidence of pericyte loss—diabetic retina on the left and age-matched control on the right. E = endothelial cells. P = pericytes. Pericytes have smaller dark-staining nuclei compared to endothelial cells, which have larger

nuclei with lighter staining. Orange outline = diabetic retinopathy. Blue outline = control. **d** A Venn diagram with the number of diabetic Nile rats having the respective conditions. Diabetic rats were defined as having each of the three conditions by using a cutoff calculated from the average count of the controls plus one standard deviation ( $n = 11$  diabetic rats and 11 control rats)

performed linear regression analyses to explore how duration of diabetes predicts our observed cellular changes: acellular capillaries ( $R^2 = 0.501, p < 0.001$ ); pericytes ( $R^2 = 0.350, p = 0.001$ ); endothelial cells ( $R^2 = 0.079, p = 0.065$ ); microglial cells ( $R^2 = 0.189, p = 0.048$ ) and retinal ganglion cells ( $R^2 = 0.016, p = 0.552$ ). At this stage, we did not observe retinal ganglion cell loss even though vascular cell loss and an increase in microglial cells were evident.

Figure 2a shows the vascular cell and acellular capillary changes as diabetes progresses. Specifically, the pericyte-to-endothelial cell ratio decreases over time during early retinopathy (Fig. 2b). Pericyte dropout is shown in Fig. 2c.


To delineate the temporal sequence further, we investigated the co-occurrence of increased acellular capillaries, pericyte dropout, and microglial infiltration in individual diabetic rats. We found that each rat observed with increased microglial cells always had vascular loss, but microglial cell numbers were unaffected in 5 out of 11 rats with vascular loss (Fig. 2d), suggesting that the vascular changes occur before microglial infiltration.

Retinal vessel caliber has been investigated as a biomarker for incidence and progression of diabetic

retinopathy for years [39], but is rarely measured in animal models. A previous population-based study limited to diabetic patients with early or lack of isolated retinopathy signs reported that larger central venular caliber, but not central arteriolar caliber, was associated with increasing HbA1c [40]. Similarly, we found that in the early progression of diabetic retinopathy in the Nile rat, CRVE linearly correlates with HbA1c ( $R^2 = 0.545, p < 0.001$ ), but CRAE did not ( $R^2 = 0.055, p = 0.333$ ).

### Progression of diabetic retinopathy

Next, we used acellular capillary counts to monitor the progression of diabetic retinopathy from the earliest stages. Consistent with a prior study [23], males developed diabetes earlier than females (Fig. 3a). Using the threshold of 16.2 acellular capillaries per mm<sup>2</sup> (explained above), we categorized diabetic rats into those with or without retinopathy. Not surprisingly, diabetic males developed retinopathy at a younger age than diabetic females (Fig. 3b, Wilcoxon test,  $p < 0.001$ ). However, both sexes did not differ in propensity to develop retinopathy when normalized for duration of diabetes (Fig. 3c, Wilcoxon test,  $p = 0.82$ ).



**Fig. 3** Progression of retinopathy in diabetic Nile rats. **a** A Kaplan–Meier graph showing the percentage of male rats ( $n = 111$ ) and female rats ( $n = 113$ ) developing diabetes over time. Males and females differed significantly (Wilcoxon test,  $\chi^2 = 25.12$ ,  $p < 0.001$ ). **b** A Kaplan–Meier graph showing the percentage of diabetic male rats ( $n = 43$ ) and female rats ( $n = 13$ ) developing retinopathy over time. Males developed retinopathy at significantly earlier ages (Wilcoxon test,  $\chi^2 = 6.383$ ,  $p < 0.05$ ). **c** A Kaplan–Meier graph presenting the same cohort of animals as panel (**b**) but normalized to duration of

diabetes. Both sexes take roughly the same duration of diabetes to develop retinopathy (Wilcoxon test,  $\chi^2 = 0.05$ ,  $p = 0.82$ ). **d** A summary of linear regression statistics between multiple variables and the number of acellular capillaries. **e** A heat map showing RBG fluctuations across age ( $n = 41$ ), sorted by increasing number of acellular capillaries. 16.2 acellular capillaries is the cutoff used to define diabetic Nile rats with retinopathy. **f** Two ROC curves depicting the usefulness of “duration of diabetes” or “mean RBG” as classifiers of retinopathy in diabetic Nile rats. AUC = area under the curve

The variation in acellular capillaries was more correlated with mean RBG than HbA1c ( $R^2 = 0.456$  for mean RBG versus 0.171 for HbA1c), and more correlated with duration of diabetes than age ( $R^2 = 0.541$  for duration of diabetes versus 0.175 for age; Fig. 3d). To illustrate RBG fluctuations in individual rats, we computed a heat map for 41 rats using RBG records up to 52 weeks old, sorted by number of acellular capillaries (Fig. 3e). To gauge the ability of

duration of diabetes or mean RBG to predict whether a Nile rat has retinopathy or not, we generated two receiver operating characteristic (ROC) curves. Using the same set of data as Fig. 3b, c, 56 diabetic rats each had an associated duration of diabetes and mean RBG, then based on acellular capillary counts, were classified as having retinopathy or not. Depending on the cutoff in the predictor (duration of diabetes or mean RBG), there will be a true positive rate and


false positive rate associated with it. ROC curves were plotted using the true positive rate versus the false positive rate for each cutoff in the predictor. How well the test variable separates between these two groups of animals is measured by the area under the curve (AUC), where  $AUC = 0.5$  means inability to separate and  $AUC = 1$  means perfect ability to separate. The AUC for duration of diabetes was 0.781,  $p = 0.001$  and the AUC for mean RBG was 0.791,  $p < 0.001$  (Fig. 3f); both predict retinopathy fairly well.

### Retinal leakage and retinal edema

We performed FFA on 40 animals (31 diabetic; 9 control) every 4 weeks from 20 to 60 weeks of age. Out of 31 diabetic rats, we only detected leakage in one, beginning with an isolated leak at 24 weeks old during pre-diabetes (Fig. 4a). However, 15 of the diabetic rats developed cataracts before 36 weeks of age and the presence of any leakage would likely have been obscured by poor image


quality. None of the control rats developed retinopathy or demonstrated leakage (Fig. 4g). From the same animals, we further analyzed eyes from 28 diabetic rats (3 had died prematurely), and confirmed retinopathy in 23 rats using acellular capillary counts. To determine whether leakage was indeed a rare event, we selected 15 older diabetic rats, 60–82 weeks of age, not compromised by cataracts that had FFA imaging done at least once. Of these, we observed leakage in 5 of them. The progression of diabetic retinopathy in one rat is shown in Fig. 4b–d, where the leakage became apparent at 48 weeks by FFA (Fig. 4c). Additionally, the fundus looked abnormal at 48 weeks (Fig. 4f), with more light reflected in a damaged area and a few bright dense spots.

As the retinal leakage progresses, it can result in edema and subsequent vision loss in patients. To detect edema in the Nile rat, we measured central retinal thickness. Compared to control rats without diabetes, 4 out of 7 diabetic retinas with retinopathy had increased retinal thickness relative to the controls (Supplementary Fig. 3A).



**Fig. 4** Retinal vascular leakage in diabetic Nile rats. **a** The progression of retinal leakage in a diabetic Nile rat. The reduced clarity of the FFA from 48 weeks onwards was not from continued leakage but rather, from cataract forming in that eye. In another diabetic rat, the area of

progressive leakage (**b–d**) is shown with the corresponding fundus images (**e, f**). The white outline marks the area where leakage developed. **g** An age-matched control to the diabetic rat in panel (**d**). Orange outline = diabetic retinopathy. Blue outline = control



**Fig. 5** Capillary non-perfusion in diabetic Nile rats. **a** FFA of a 52-week-old Nile rat exhibiting leakage and capillary non-perfusion (inset dotted line). **d** A magnified version of the orange dotted rectangle in panel (a) juxtaposed with a similar region in the retina of an age-matched control on the right. **b** A trypsin digest of the same retina as panel (a) but 8 weeks later, at 60 weeks old. The rounded rectangle

shows the border of capillary non-perfusion, magnified in panel (e). An age-matched control of panel (b) is shown in panel (c), magnified in panel (f). Scale bars for panels (b) and (c) = 200  $\mu$ m. Scale bars for panels (e) and (f) = 50  $\mu$ m. V = central retinal vein. Arrow = acellular capillary. E = endothelial cell. P = pericyte. Orange outline = diabetic retinopathy. Blue outline = control


Interestingly, only the 4 out of 7 diabetic retinas with increased thickness presented with gliosis (Supplementary Fig. 3B), suggesting that glial dysfunction could be linked to edema.

### Capillary non-perfusion

Clinically, capillary non-perfusion is described as localized areas void of patent blood vessels on the FFA and is a feature of diabetic retinal ischemia. Trypsin digest of post-mortem retinas of patients with diabetic retinal ischemia reveals significant areas of capillary loss, indicating capillary non-perfusion in that area [41]. A similar phenotype was observed in diabetic Nile rats. In the FFA of one diabetic Nile rat, in addition to the obvious leakage seen as small round pools of fluorescein, we observed an area with an abnormally low density of perfused retinal vessels near the optic nerve head (Fig. 5a). To highlight the sparse vessel density, a comparison image of a control rat is shown side-by-side (Fig. 5d). The margin of capillary non-perfusion was more clearly depicted in a trypsin digest of the same retina (Fig. 5b). Within this area, at higher magnification, almost all endothelial cells and pericytes were visibly absent, leaving several empty basement membrane tubes (Fig. 5e). This was in conspicuous contrast to age-matched rats without diabetes (Fig. 5c, f). Out of 64 diabetic retinas analyzed, we found 4 with capillary non-perfusion.

### Proliferative diabetic retinopathy

Proliferative diabetic retinopathy is an advanced stage of the disease and leads to loss of vision, generally from ischemia, hemorrhage, and fibrosis [17, 42]. We identified two diabetic Nile rats with proliferative diabetic retinopathy, where the neovascularization appeared above the retinal surface based on confocal imaging. In the first rat, neovascularization stemming from one retinal artery was isolated digitally from a z-stack confocal image to illustrate the spatial location (Fig. 6a). Figure 6b–d is from the second rat with severe proliferative diabetic retinopathy, that presented with intraocular hemorrhage when alive. In advanced diabetic retinopathy, neovascularization often extends through the inner limiting membrane of the retina into the vitreous resulting in vitreous hemorrhage. In this rat, the central retinal arteries had uneven vessel caliber, depicted by brackets (Fig. 6b), compared to the homogenous vessel caliber in healthy rats (Fig. 6c). Intriguingly, aberrant neovascularization, evidenced by collagen IV labeling of dense tortuous fine vessels, appeared to be closer to the retinal vein (Fig. 6b). This is in line with the human disease, where the neovascularization develops from the venous side of the retinal circulation [41]. Coming from a location in this same retina closer to the optic nerve head, fibrotic tissue, as defined by morphology, can be observed (Fig. 6d), in contrast with healthy retinal vessels (Fig. 6e). Specifically, this compromised retina showed greatly reduced NG2-positive



**Fig. 6** Neovascularization in diabetic Nile rats. **a** The spatial orientation of pre-retinal neovascularization in a rat with proliferative diabetic retinopathy. Using Imaris software, a smoothed surface was created from an isolated retinal artery stained with Col IV. The superficial retinal vessels were artificially colored in green and the pre-retinal neovascularization colored in red. **b** Uneven caliber of retinal artery in a diabetic retina, highlighted by brackets and neovascularization, highlighted by multiple arrows, which is denser around the retinal vein. A = central retinal artery. V = central retinal vein. **c** An age-


matched control of panel (**b**). **d** Fibrotic tissue and neovascularization around the optic nerve head at the top right corner. Col IV highlights the neovascularization and NG2 highlights the absence of pericytes. **e** An age-matched control of panel (**d**). Panels (**b**), (**d**), and (**f**) are from the same diabetic retina. **f** A retinal trypsin digest micrograph. **g** An age-matched control of panel (**f**). CL = capillary loop. PG = pericyte ghost. MA = microaneurysm. E = endothelial cell. P = pericyte. Scale bar = 50  $\mu$ m. Orange outline = diabetic retinopathy. Blue outline = control

pericytes (Fig. 6d) compared to a healthy retina with evenly spaced pericytes along the vessels (Fig. 6e). The absence of both endothelial cells and pericytes was confirmed in the trypsin digest, performed on the same retina after immunolabeling (Fig. 6f). In a healthy retina, the nuclei of the endothelial cells and pericytes were clearly stained (Fig. 6g). In Fig. 6f, a few stained nuclei appeared to be neither endothelial cells nor pericytes, but rather unwashed neuronal cells from the trypsin digest procedure. Additional vascular lesions in this retina included capillary loops, pericyte ghosts, and microaneurysms (Fig. 6f).

### Intraretinal microvascular abnormalities


In patients, intraretinal microvascular abnormalities are a major risk factor for progression to proliferative diabetic retinopathy [43] and their fundus morphology is clearly

defined, but this feature is rarely and vaguely described in animal models [44]. Upon post-mortem immunofluorescence analysis and trypsin digest of diabetic Nile rats, we identified 8 out of 45 with distinctive abnormalities within the retinal thickness (Fig. 7a, c) that involved microvascular torsion, much like intraretinal microvascular abnormalities in patients. These microvascular abnormalities were only seen with a prolonged duration of diabetes, with a dramatic increase at around 60 weeks of diabetes (Fig. 7b). Aforementioned microvascular abnormalities in the diabetic Nile rat included dilated tortuous capillaries (Fig. 7d, e), abnormally branched capillaries (Fig. 7g, h), and arteriolar–venular shunts (Fig. 7j, k). Evenly spaced pericytes were absent in these aberrant regions compared to elsewhere within the same retina (Fig. 7f). Additionally, these abnormal areas revealed an obviously higher density of acellular capillaries (Fig. 7e, h, k).



**Fig. 7** Intraretinal microvascular abnormalities in diabetic Nile rats. **a** A retinal trypsin digest of a diabetic Nile rat with multiple regions of microvascular abnormalities. Insets are magnified as panels **(d)** and **(g)**. Scale bar = 200  $\mu\text{m}$ . **b** A Kaplan–Meier graph showing the percentage of diabetic Nile rats developing any retinopathy (>16.21 acellular capillaries/ $\text{mm}^2$ ) versus a proportion of them developing intraretinal microvascular abnormalities (confirmed by immunohistochemistry and trypsin digests). **c** An age-matched control exhibiting evenly spaced pericytes along the retinal capillaries. P = pericyte. **d** Loss of pericytes and abnormal branched capillaries. **e** Same area as

panel **(d)**, after trypsin digest. The insets in panels **(d)** and **(e)** mark the same vessel. **f** Aberrant retinal vessels surrounding the optic nerve head, highlighted by white arrows. Age-matched control depicted in panel **(i)**. **g** Magnified from panel **(f)**. **h** Same area as panel **(g)**, after trypsin digest. The insets in panels **(f)**, **(g)**, and **(h)** mark the same vessel. **j** Another area with intraretinal microvascular abnormalities from the same retina but not within the field of view in panel **(a)**. **k** Same area as panel **(j)**, after trypsin digest. The insets in panels **(j)** and **(k)** mark the same vessels. Black arrows = acellular capillaries. Scale bars in **(c–e, g, h, j, k)** = 50  $\mu\text{m}$ . Scale bars in **(f)** and **(i)** = 100  $\mu\text{m}$ .



**Fig. 8** Microglial infiltration during diabetic retinopathy in the Nile rat. **a** Abnormally high density of microglial cells in a retina with proliferative diabetic retinopathy. **b** An age-matched control of panel (a). **c** An activated microglial cell at high magnification from the same retina as in panel (a). **d** A resting microglial cell at high magnification

from the same retina as in panel (b). **e** Several microglial cells surround a highly tortuous arteriolar structure in a diabetic retina. **f** A few microglial cells surround a dilated venule in a diabetic retina. Scale bars of (a, b, e, f) = 50  $\mu$ m. Scale bar of (c) and (d) = 10  $\mu$ m

### Other retinal microvascular abnormalities in diabetic Nile rats

Microaneurysms, though frequently observed in humans, were only rarely observed in the Nile rat (Supplementary Fig. 4A). Other features found in diabetic Nile rats included capillary loops and re-duplications (Supplementary Figs. 4B and C), venous beading, dilated venules, venular occlusion, and arterial tortuosity (Supplementary Figs. 4D–I).

### Spatial distribution of microglial cell infiltration

Our earlier data (Fig. 2) suggested that microglial infiltration begins near the time of the initial vascular changes in Nile rat diabetic retinopathy. In the Nile rat retina, we observed a wide distribution of microglial cells without specific patterns linked to retinopathy (Supplementary Fig. 5). We did not have identical spatial resolution for the microglial cell and acellular capillary distributions in the above data set to examine co-localization directly. In later studies, we examined several advanced diabetic retinas for the presence of vascular lesions and microglial cells. In the retina exhibiting proliferative diabetic retinopathy shown in

Fig. 6b–d, a conspicuously high density of microglial cells covered the entire retina, the majority of which appeared to be activated microglial cells (Fig. 8a, c; control, Fig. 8b, d). Microglial cells also tended to surround arteriolar and venular abnormalities (Fig. 8e, f). Our data suggests that inflammation and vascular changes are closely linked both temporally and spatially.

### Lipemia retinalis

Lipemia retinalis is a rare manifestation of hyperlipemia associated with diabetic patients, where the retinal veins and arteries are pink-to-creamy-white color on the fundus imaging [45]. 20% of Nile rats with diabetic retinopathy presented lipemia retinalis (Supplementary Fig. 6).

### Discussion

The earliest changes that occur in the diabetic retina remain poorly understood, hindered by insufficient histological material from human donors and a lack of animal models that accurately mirror the human condition. Because of the

limited resolution, clinical imaging studies cannot reveal the earliest cellular changes in diabetic retinopathy, and it is those earliest changes that should offer the greatest insights into the events that initiate the disease. Because appropriately staged human material is so difficult to obtain, more accurate animal models that mimic the natural history of diabetic retinopathy in humans are urgently needed. The Nile rat is a well-documented animal model for nutritionally induced type 2 diabetes, so here we sought to better document the temporal progression and range of lesions observed in diabetic retinopathy in this animal model.


It is challenging to pin down the sequence of events leading to the development of diabetic retinopathy. As with the human population, the progression of type 2 diabetes and subsequent development of diabetic retinopathy is highly variable in the Nile rats, thus a large sample size is required. To identify the earliest events, we selected young rats from 20 to 44 weeks of age. Since duration of diabetes is one of the most important risk factors for diabetic retinopathy, by conducting a linear regression study based on duration of diabetes, we highlighted the continuous relationship of observed cellular changes to the development of diabetic retinopathy.

After 36 weeks of diabetes, acellular capillaries increased by about 300% and pericytes decreased by about 25%, but a progressive endothelial cell loss was not obvious. At 0 weeks of diabetes, there were only ~10 acellular capillaries, ~950 endothelial cells, and ~700 pericytes per square millimeter of retina. Because of the very low initial number of acellular capillaries, a modest increase to ~30 acellular capillaries was statistically significant. The relatively large number of endothelial cells at 0 weeks and the variation in numbers between animals would explain why a loss of endothelial cells comparable to the increase in acellular capillaries would not yet be statistically significant during this early period. Nonetheless, there was already a significant decline in pericyte numbers during this period. Preferential loss of pericytes and accelerated accumulation

of acellular capillaries are consistent with studies done with diabetic donor eyes without advanced retinopathy lesions [46, 47].

As acellular capillaries increased and pericytes decreased, microglial cells increased by about 20%, but retinal ganglion cell loss was not detected. This suggests that neurodegeneration, as typified by retinal ganglion cell loss, lags behind vascular degeneration and microglial cell infiltration during the development of retinopathy in the diabetic Nile rat. To further delineate the temporal sequence of events, we inspected vascular and microglial cellular changes in 11 individual rats, and found that some retinas with retinal vascular degeneration did not have increased microglial cells but all retinas with increased microglial cells also exhibited vascular degeneration. Taken together, our data support vascular degeneration as the initiating event of diabetic retinopathy in the Nile rat.

Our results document that the Nile rat exhibits a diabetic retinopathy that shares a range of lesions with the human condition (Fig. 9). Importantly, in this model, we found in the Nile rat retinal pathology similar to the three clinical conditions responsible for vision loss, namely edema, capillary non-perfusion, and proliferative diabetic retinopathy. This animal model is not without its limitations, however. First, although the range of lesions overlaps considerably with the human condition, the frequency of some lesions, notably microaneurysms, differs considerably. Second, most of the older diabetic animals develop cataracts; so assessing the function of the retina in animals with advanced disease is difficult. And third, similar to the human condition, the timing of the onset of diabetes and the subsequent onset of diabetic retinopathy is variable and the experiments require prolonged timeframes of many months. However, because the onset of type 2 diabetes in the Nile rat can be consistently induced by dietary manipulations that parallel the dietary changes linked to the human condition, this animal model does have



**Fig. 9** Progression of diabetic retinopathy in the Nile rat. In our cohort, 75% of diabetic rats  $\geq 24$  weeks old had increased acellular capillaries, mean RBG  $\geq 128$  mg/dL; duration of diabetes  $\geq 8$  weeks; 17% of diabetic rats  $\geq 32$  weeks old had lipemia retinalis, mean RBG  $\geq 235$  mg/dL; duration of diabetes  $\geq 24$  weeks, 23% of diabetic rats  $\geq 45$  weeks old had microvascular abnormalities, mean RBG  $\geq 277$  mg/dL,

duration of diabetes  $\geq 32$  weeks; 3% of diabetic rats  $\geq 52$  weeks old had localized extensive capillary loss, mean RBG  $\geq 237$  mg/dL, duration of diabetes  $\geq 30$  weeks; 7% of diabetic rats  $\geq 68$  weeks old had proliferative diabetic retinopathy, mean RBG  $\geq 448$  mg/dL, duration of diabetes  $\geq 48$  weeks

great promise for identifying and testing novel therapies for both type 2 diabetes and diabetic retinopathy.

**Acknowledgements** This study was supported by The Garland Initiative for Vision funded by the William K. Bowes Jr. Foundation; NIH grant EY-019968 and core facility grants to the Waisman Center from NICHD (U54 HD090256) and to the NRI-MCDB Microscopy Facility from NSF MRI (DBI-1625770). The authors thank the K.C. Hayes lab for the founder Nile rats of the colony and for valuable advice on Nile rat husbandry and nutrition. The authors also thank the W. Stallcup lab for their antibody gift.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35:556–64.
2. Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387:1513–30.
3. Chen MS, Kao CS, Chang CJ, Wu TJ, Fu CC, Chen CJ, et al. Prevalence and risk-factors of diabetic-retinopathy among noninsulin-dependent diabetic subjects. *Am J Ophthalmol*. 1992;114:723–30.
4. Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, et al. Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea. *Diabetes Metab J*. 2016;40:482–93.
5. Penman A, Hancock H, Papavasileiou E, James M, Idowu O, Riche DM, et al. Risk factors for proliferative diabetic retinopathy in African Americans with type 2 diabetes. *Ophthalmic Epidemiol*. 2016;23:88–93.
6. Ahmed RA, Khalil SN, Al-Qahtani MA. Diabetic retinopathy and the associated risk factors in diabetes type 2 patients in Abha, Saudi Arabia. *J Family Community Med*. 2016;23:18–24.
7. Rajalakshmi R, Amutha A, Ranjani H, Ali MK, Unnikrishnan R, Anjana RM, et al. Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset type 1 and type 2 diabetes. *J Diabetes Complications*. 2014;28:291–7.
8. Yoshida Y, Hagura R, Hara Y, Sugawara G, Akanuma Y. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. *Diabetes Res Clin Pract*. 2001;51:195–203.
9. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis*. 2015;2:17.
10. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. *Arch Ophthalmol*. 1961;66:366–78.
11. Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: mechanisms and consequences. *Curr Med Chem*. 2013;20:3218–25.
12. Kern TS, Engerman RL. Vascular lesions in diabetes are distributed non-uniformly within the retina. *Exp Eye Res*. 1995;60:545–9.
13. Powell ED, Field RA. Diabetic retinopathy and rheumatoid arthritis. *Lancet*. 1964;2:17–8.
14. Wolter JR. Diabetic retinopathy. *Am J Ophthalmol*. 1961;51:1123–41.
15. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. *Ophthalmology*. 1984;91:1464–74.
16. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early treatment diabetic retinopathy study report #18. *Invest Ophthalmol Vis Sci*. 1998;39:233–52.
17. Bresnick GH, De Venecia G, Myers FL, Harris JA, Davis MD. Retinal ischemia in diabetic retinopathy. *Arch Ophthalmol*. 1975;93:1300–10.
18. Olivares AM, Althoff K, Chen GF, Wu S, Morrisson MA, DeAngelis MM, et al. Animal models of diabetic retinopathy. *Curr Diabetes Rep*. 2017;17:93.
19. Cai X, McGinnis JF. Diabetic retinopathy: animal models, therapies, and perspectives. *J Diabetes Res*. 2016;2016:3789217.
20. Jiang X, Yang L, Luo Y. Animal models of diabetic retinopathy. *Curr Eye Res*. 2015;40:761–71.
21. Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. *Lipids*. 2009;44:297–309.
22. Snorgaard O, Poulsen GM, Andersen HK, et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. *BMJ Open Diabetes Res Care*. 2017;5:e000354.
23. Chaabo F, Pronczuk A, Maslova E, Hayes K. Nutritional correlates and dynamics of diabetes in the Nile rat (*Arvicanthis niloticus*): a novel model for diet-induced type 2 diabetes and the metabolic syndrome. *Nutr Metab*. 2010;7:29.
24. Bolsinger J, Pronczuk A, Hayes KC. Dietary carbohydrate dictates development of type 2 diabetes in the Nile rat. *J Nutr Biochem*. 2013;24:1945–52.
25. Yang K, Gotzmann J, Kuny S, Huang H, Sauve Y, Chan CB. Five stages of progressive beta-cell dysfunction in the laboratory Nile rat model of type 2 diabetes. *J Endocrinol*. 2016;229:343–56.
26. Subramaniam A, Landstrom M, Luu A, Hayes KC. The Nile rat (*Arvicanthis niloticus*) as a superior carbohydrate-sensitive model for type 2 diabetes mellitus (T2DM). *Nutrients*. 2018;10:E235.
27. Noda K, Nakao S, Zandi S, Sun D, Hayes KC, Hafezi-Moghadam A. Retinopathy in a novel model of metabolic syndrome and type 2 diabetes: new insight on the inflammatory paradigm. *FASEB J*. 2014;28:2038–46.
28. Han WH, Gotzmann J, Kuny S, Huang H, Chan CB, Lemieux H, et al. Modifications in retinal mitochondrial respiration precede type 2 diabetes and protracted microvascular retinopathy. *Invest Ophthalmol Vis Sci*. 2017;58:3826–39.
29. Noda K, Melhorn MI, Zandi S, Frimmel S, Tayyari F, Hisatomi T, et al. An animal model of spontaneous metabolic syndrome: Nile grass rat. *FASEB J*. 2010;24:2443–53.
30. Bolsinger J, Landstrom M, Pronczuk A, Auerbach A, Hayes KC. Low glycemic load diets protect against metabolic syndrome and type 2 diabetes mellitus in the male Nile rat. *J Nutr Biochem*. 2017;42:134–48.
31. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Colocalization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. *J Neurosci Res*. 1996;43:299–314.
32. Schmitz C, Eastwood BS, Tappan SJ, Glaser JR, Peterson DA, Hof PR. Current automated 3D cell detection methods are not a suitable replacement for manual stereologic cell counting. *Front Neuroanat*. 2014;8:27.

33. Chou JC, Rollins SD, Fawzi AA. Trypsin digest protocol to analyze the retinal vasculature of a mouse model. *J Vis Exp*. 2013;76:e50489.
34. Dietrich N, Hammes HP. Retinal digest preparation: a method to study diabetic retinopathy. *Methods Mol Biol*. 2012; 933:291–302.
35. Perez-Rovira A, MacGillivray T, Trucco E, Chin KS, Zutis K, Lupascu C, et al. VAMPIRE: Vessel Assessment and Measurement Platform for Images of the REtina. *Conf Proc IEEE Eng Med Biol Soc*. 2011;2011:3391–4.
36. Brown WR. A review of string vessels or collapsed, empty basement membrane tubes. *J Alzheimers Dis*. 2010;21:725–39.
37. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. *Br J Ophthalmol*. 1963;47:521–38.
38. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. *Diabetes*. 2011;60:9–16.
39. Ding J, Ikram MK, Cheung CY, Wong TY. Retinal vascular calibre as a predictor of incidence and progression of diabetic retinopathy. *Clin Exp Optom*. 2012;95:290–6.
40. Nguyen TT, Wang JJ, Sharrett AR, Islam FM, Klein R, Klein BE, et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). *Diabetes Care*. 2008;31:544–9.
41. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? *Eye*. 2009;23:1496–508.
42. Roy S, Amin S, Roy S. Retinal fibrosis in diabetic retinopathy. *Exp Eye Res*. 2016;142:71–5.
43. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. *Ophthalmology*. 1991;98:823–33.
44. Kern TS, Engerman RL. Galactose-induced retinal microangiopathy in rats. *Invest Ophthalmol Vis Sci*. 1995;36:490–6.
45. Fyfe WM, Hall MS, Scott JW. Lipaemia-retinalis in untreated diabetes mellitus. *Arch Dis Child*. 1970;45:84.
46. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. *J Clin Invest*. 1996;97:2883–90.
47. Li W, Yanoff M, Liu X, Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. *Chin Med J*. 1997;110:659–63.